Hemodynamic monitoring and vasodilator therapy in acute left ventricular failure. Preliminary report on a new vasodilator, tolmesoxide.
Data, obtained by invasive hemodynamic monitoring, are now routinely available in our Intensive Care Unit, and are processed by means of a small calculator to a cardiovascular profile, including O2 transport/consumption, vascular resistance and ventricular work values. Patients with clinically persistent shock states, after 12-24 hours optimal classical cardiovascular therapy, are invasively studied. Vasodiltor therapy frequently improves not only hemodynmic parameters, but also oxygen delivery to the tissues. Tolmesoxide, a new peripheal vasodilator, has been used in eleven patients. Preliminary results are discussed.
D000208:Acute Disease; D000368:Aged; D006352:Heart Ventricles; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007700:Kinetics; D008875:Middle Aged; D009599:Nitroprusside / Q000627:therapeutic use; D010101:Oxygen Consumption / Q000187:drug effects; D012770:Shock, Cardiogenic / Q000188:drug therapy*; D013454:Sulfoxides / Q000627:therapeutic use*; D013618:Tachyphylaxis; D014050:Toluene / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D013454:Sulfoxides; D014665:Vasodilator Agents; D009599:Nitroprusside; D014050:Toluene; C016152:tolmesoxide